Application of GPX4+CD8 + T cell subset as sepsis clinical biomarker

By detecting the GPX4+CD8+ T cell levels in peripheral blood, the problem of insufficient diagnostic accuracy of sepsis in the prior art is solved, and a new biomarker is provided that can effectively evaluate the severity of septic patients and Predicting the progress of the disease improves the accuracy of diagnosis and treatment.

CN118962131APending Publication Date: 2024-11-15JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411131274.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

There is insufficient accuracy in the existing diagnostic and prediction methods of sepsis, and new biomarkers are needed to improve the predictive ability of diagnosis and disease outcomes.

Method used

By detecting the levels of GPX4+CD8+ T cells in peripheral blood, we provide a method to evaluate the severity of patients with sepsis and develop relevant diagnostic kits, including detection of total T lymphocytes, total B lymphocytes, and auxiliary Number and proportion of /induced T lymphocytes, natural killer cells, inhibitory/cytotoxic T lymphocytes and GPX4+CD8+ T cells.

Benefits of technology

The diagnostic accuracy and treatment targeting of sepsis patients have been significantly improved. The GPX4+CD8+ T cell level is positively correlated with the severity of the disease, which can predict the progress and clinical results of sepsis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962131A_ABST
    Figure CN118962131A_ABST
Patent Text Reader

Abstract

The invention relates to a method for evaluating severity of a sepsis patient by detecting GPX4 + CD8 + T cell level in peripheral blood. The method comprises the following steps: collecting a peripheral blood sample of the sepsis patient; treating the sample with an anticoagulant; separating the PBMC cells and labeling the PBMC cells by using an antibody; calculating immune cell proportion data; evaluating the severity of the illness state according to a detection result; the calculation of the immune cell proportion data is to detect the number and proportion of total T lymphocytes (CD3 + CD19-), total B lymphocytes (CD3-CD19 +), auxiliary / induced T lymphocytes (CD3 + CD4 +), natural killer cells (CD3-CD19-CD56 +), inhibition / cytotoxic T lymphocytes (CD3 + CD8 +) and GPX4 + CD8 + T cells through flow cytometry. The invention also provides a sepsis or sepsis prognosis diagnosis kit and application thereof. By detecting the level of GPX4 + CD8 + T cells in peripheral blood, a novel and effective method is provided for prognosis evaluation of sepsis patients, and the diagnosis accuracy and the treatment pertinence are expected to be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the application of GPX4+CD8+T cell subpopulation in peripheral blood of sepsis patients as a clinical biomarker of sepsis. Background Art

[0002] Sepsis is a systemic inflammatory response syndrome caused by infection, which has high morbidity and mortality. Existing methods for diagnosing and predicting the severity of sepsis have certain limitations, and new biomarkers need to be developed to improve diagnostic accuracy and predict disease outcomes.

[0003] Glutathione peroxidase 4 (GPX4) is a key antioxidant enzyme that plays an important role in maintaining the integrity of cell membranes and preventing lipid peroxidation. Its physiological functions and pathological significance are as follows: 1. Antioxidant effect: GPX4 is the only enzyme that can reduce phospholipid hydroperoxides, protecting cell membranes from damage caused by lipid peroxidation. This is essential for maintaining the structure and function of cell membranes. 2. Regulation of cell apoptosis: GPX4 protects cells from apoptosis and necrosis caused by oxidative damage by preventing the accumulation of lipid peroxidation products. 3. Enzymes essential for embryonic development: GPX4 is essential during embryonic development, and its loss can lead to early embryonic death, indicating its importance in normal growth and development.

[0004] Pathological significance: 1. Key regulator of ferroptosis: GPX4 is a key factor in regulating ferroptosis (an iron-dependent form of cell death). Reduced or absent GPX4 activity leads to the accumulation of lipid peroxides, triggering ferroptosis; this is associated with the pathological processes of a variety of diseases such as neurodegenerative diseases, cancer, and cardiovascular diseases. 2. Association with neurodegenerative diseases: Studies have shown that GPX4 dysfunction may be associated with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, one of the common pathological features of these diseases is oxidative stress and lipid peroxidation. 3. Dual role in cancer: The role of GPX4 in cancer is more complex. On the one hand, it protects the survival of cancer cells by inhibiting ferroptosis; on the other hand, the antioxidant effect of GPX4 can prevent normal cells from transforming into cancer cells. Therefore, the regulation of GPX4 has become an important direction in cancer treatment research. 4. Protective effect on cardiovascular disease: GPX4 plays a protective role in the cardiovascular system by preventing lipid peroxidation, and its loss may lead to the occurrence and development of cardiovascular diseases such as atherosclerosis.

[0005] GPX4 plays a key role in cellular antioxidant defense, regulating ferroptosis, and maintaining cell membrane integrity. Its dysfunction is closely related to the pathological process of various diseases. Understanding the physiological function and pathological significance of GPX4 will help develop new treatment strategies for various diseases. Previous studies by the research team have shown that the expression level of GPX4 in CD8+T cells may be related to the pathophysiological process of sepsis.

[0006] However, there are currently no reports on the use of GPX4+CD8+T cell subsets in peripheral blood as clinical biomarkers of sepsis in patients with sepsis. Summary of the invention

[0007] The purpose of the present invention is to provide the application of GPX4+CD8+T cell subsets as clinical biomarkers of sepsis in view of the deficiencies in the prior art.

[0008] In a first aspect, the present invention provides a method for assessing the severity of a sepsis patient by detecting the level of GPX4+CD8+T cells in peripheral blood, the method comprising:

[0009] a. Collect peripheral blood samples from patients with sepsis;

[0010] b. Treat the sample with an anticoagulant;

[0011] c. Isolate PBMC cells and label them with antibodies;

[0012] d. Calculate the immune cell ratio data;

[0013] e. Assess the severity of the disease based on the test results;

[0014] The calculated immune cell ratio data is obtained by flow cytometry to detect the number and ratio of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells.

[0015] In a second aspect, the present invention provides a reagent for detecting the number and proportion of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells in the preparation of a sepsis or sepsis prognosis diagnostic kit.

[0016] As a preferred example, the sample to be detected is blood.

[0017] In a third aspect, the present invention provides a diagnostic kit for sepsis or sepsis prognosis, the diagnostic kit comprising reagents for detecting the number and proportion of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells.

[0018] In a fourth aspect, the present invention provides the use of a reagent for detecting GPX4+CD8+T cell subsets in the preparation of a sepsis or sepsis prognosis diagnostic kit.

[0019] As a preferred example, the sample to be detected is blood.

[0020] In a fifth aspect, the present invention provides a diagnostic kit for sepsis or sepsis prognosis, wherein the diagnostic kit comprises a reagent for detecting GPX4+CD8+T cell subsets.

[0021] The advantages of the present invention are that the level of GPX4+CD8+T cells in the peripheral blood of patients with sepsis is significantly higher than that of the healthy control group, and the level of GPX4+CD8+T cells is positively correlated with the severity of the patient's condition. The absolute counts of CD3+T cells, CD4+T cells, CD8+T cells, B cells, natural killer cells, and GPX4+CD8+T cells in the improved group are significantly higher than those in the severe group. GPX4+CD8+T cell counts can predict the progression of sepsis. Lymphocytopenia and CD8+T cell exhaustion are associated with the clinical outcomes of sepsis, indicating that CD8+T cells, especially GPX4+CD8+T cells, have the potential to serve as predictive biomarkers and therapeutic targets for patients with sepsis. The present invention provides a new and effective method for evaluating the prognosis of patients with sepsis by detecting the level of GPX4+CD8+T cells in peripheral blood, which is expected to improve the accuracy of diagnosis and the pertinence of treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 :Peripheral blood immune cell populations and characteristics in patients with sepsis.

[0023] Figure 2 : Analysis of CD8 T cell subsets.

[0024] Figure 3 : GPX4 CD8 T cells are associated with sepsis phenotype. DETAILED DESCRIPTION

[0025] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0026] Example 1

[0027] 1. Collect clinical samples

[0028] From 2021 to 2023, we collected 36 peripheral blood samples from patients in Jinshan Hospital Affiliated to Fudan University and treated the samples with the anticoagulant EDTA-Na2 to prevent blood coagulation. The samples were divided into three groups, including 15 cases in the sepsis group, 15 cases in the septic shock group, and 6 cases in the healthy control group.

[0029] (1) Inclusion criteria:

[0030] 1) Sepsis group: ① patients aged ≥18 years and ≤65 years, regardless of gender; ② patients with sepsis who met the Sepsis 3.0 criteria proposed by the 2016 international sepsis expert consensus, that is, patients with infection or suspected infection, when the sepsis-related sequential organ failure SOFA score increased by ≥2 points compared with the baseline; ③ patients who did not meet the septic shock criteria according to the Sepsis 3.0 criteria.

[0031] 2) Septic shock group: ① patients aged ≥18 years and ≤65 years, regardless of gender; ② patients with sepsis who meet the Sepsis 3.0 criteria proposed by the 2016 international sepsis expert consensus, that is, patients with infection or suspected infection, when the sepsis-related sequential organ failure SOFA score increases by ≥2 points compared with the baseline; ③ patients who meet the septic shock criteria according to the Sepsis 3.0 criteria: ① pressor therapy is still required to maintain MAP ≥65 mmHg under appropriate fluid replacement;

[0032] ② Patients with septic shock with blood lactate level >2mmol / L.

[0033] 3) Healthy control group: ① Age ≥ 18 years and ≤ 65 years, regardless of gender; ② No immune-related diseases. (2) Exclusion criteria: ① Infected patients who do not meet the Sepsis 3.0 diagnosis; ② Patients with congenital immunodeficiency, tumors, rheumatic immune system diseases, blood system diseases, and patients who have used hormones or immunomodulatory drugs within 1 month after organ transplantation; ③ Patients with difficult-to-control neurological, psychiatric or mental disorders, poor compliance, and inability to cooperate; ④ Patients who have participated in other clinical trials; ⑤ Patients deemed by the researchers to be unsuitable for this study.

[0034] 2. Preparation of fresh sample marker samples

[0035] Place the blood collection tube in a centrifuge at 3000RPM, with the centrifuge speed at the lowest setting. After centrifugation for 10 minutes, aspirate the serum for storage and fill it with PBS to the original position. Add 5ml of lymphocyte separation solution to a new 15ml centrifuge tube, slowly add the blood diluted with PBS to the inclined lymphocyte separation solution tube, and centrifuge at 3000RPM for 30 minutes. Aspirate the middle layer of white membrane into a new 15ml centrifuge tube, add PBS in a 1:1 ratio, gently invert, and centrifuge at 1500RPM for 5 minutes. in; after discarding the supernatant, use 2ml lysis solution to resuspend the precipitate, let it stand for 3min, add culture medium to stop lysis, centrifuge at 1100RPM for 5min, discard the supernatant, resuspend the precipitate with 5ml PBS, centrifuge at 1100RPM for 5min; after discarding the supernatant, add 50ul antibody mixture (antibody: PBS = 1: 200) to the cell precipitate, and stain it at room temperature and away from light for 15min; after staining, wash it once with 1×PBS, 1500rpm, 5min; after centrifugation to obtain the cell precipitate, add 500ul 1×PBS to resuspend the cells in the flow cytometry sample tube. Filter with a 300-400 mesh filter before the upper level, and place it on ice away from light after filtering and wait for detection. Finally, analyze the cells with a flow cytometer (BD, USA).

[0036] 3. Data processing method

[0037] After obtaining the data, Flowjo V10 analysis software was used to analyze the number and proportion of the following types of cells. Grphpad prism 8.0 was used for data analysis and processing between groups, and t-test was used; p < 0.05 was considered statistically significant.

[0038] 4. Specific testing content

[0039]

[0040] 5. Experimental reagents

[0041]

[0042] 6. Clinical application:

[0043] -Establish reference ranges to predict the severity of sepsis based on test results.

[0044] 7. Experimental data support: see Figure 1 , Figure 2 , Figure 3

[0045] Figure 1Clustering and characteristics of peripheral blood immune cells in patients with sepsis. Peripheral blood mononuclear cells were collected and isolated from patients with urinary sepsis (n=30 cases) and healthy controls (n=6 cases), including 15 patients with sepsis and 15 patients with septic shock. All were sequenced and the results were analyzed by spectral clustering. (A) Immune cells from different sources have different distributions. Single cell data were analyzed by UMAP dimensionality reduction and divided into 4 groups: control: healthy control; Sepsis: sepsis; Septic shock: septic shock; After treatment: 14 days after treatment, sepsis was effectively controlled and the patient was in the recovery period. (B) Through the expression of key marker genes for cell classification, we found that peripheral blood immune cells in patients with sepsis mainly include monocytes, DC, T, B, NK and other major types; monocytes and T cells accounted for the largest proportion. (C) It was found that a group of gene modules coexisted among the four groups, but the expression intensity was different, indicating that some cellular and molecular events changed significantly among the groups. (D) Functional analysis of these co-expressed gene modules revealed that they mainly focused on functions such as cytokine signal transduction and T cell activation.

[0046] Figure 2 Analysis of CD8 T cell subsets. (A) Through clustering, we identified 6 different CD8 T cell subsets (0-5), including naive, effector, memory, and exhausted T cells; (B) Peripheral blood mononuclear cell flow cytometry antibody staining and T cell typing revealed that the number of peripheral blood CD8 TCM cells in patients who died of sepsis on the third day was significantly less than that in patients who survived later (P<0.01), suggesting that the status of CD8 T cells is related to the prognosis of patients; (C) Heat map of key marker gene expression of each CD8 T cell subset (0-5), including genes encoding naive / memory, effector, co-stimulatory signal, immune co-inhibitory molecules, transcription factors, etc.; (D) Heat map of the most strongly expressed genes in each CD8 T cell subset (0-5).

[0047] Figure 3GPX4 CD8 T cells are associated with sepsis phenotype. (A) Through clustering, we identified a total of 6 different CD8 T cell subsets including naive, effector, memory and exhausted T cells; and further divided them into 3 immune states (sck0, sck1, sck2); (B) Gene expression heat maps corresponding to the 3 states; sck1 not only highly expressed some inflammation-related genes (LYZ, FCN1, SERPINA, etc.), but also highly expressed GPX4; (C) If the CD8 T cells of sepsis patients (sepsis + septic shock) were combined, it was found that their distribution was significantly different from that of healthy controls; (D) Correlation analysis showed that the sck1 state was specifically associated with sepsis; (E) Comparison of highly expressed signaling pathways in the cell populations of the 3 immune states (sck0, sck1, sck2).

[0048] Preliminary experimental results showed that the level of GPX4+CD8+T cells in the peripheral blood of patients with sepsis was significantly higher than that in the healthy control group, and the level of GPX4+CD8+T cells was positively correlated with the severity of the patient's condition.

[0049] In the early stage of this project, the peripheral blood immune map of sepsis patients has been established through single-cell sequencing:

[0050] In the early stage of the project, peripheral blood mononuclear cells were collected and separated from patients with urinary sepsis (n = 30 cases) and healthy controls (n = 6 cases). Specimens from patients with sepsis were collected at four time points after hospitalization: 0, 3, 7, and 14 days. The total PBMCs (5,000-10,000 cells per patient per time point) were analyzed using single-cell 3'RNA tag sequencing, and a dynamic peripheral immune map was constructed; cells were first clustered in two steps: low-resolution clustering to identify the main immune cell types, and then sub-clustering of each cell type, and finally 35 immune cell subtypes in the peripheral blood of patients with sepsis were determined, including the transcriptional status of major immune cells such as monocytes, T, B, and NK; the changes in the proportion of monocytes and T cells were the most different between the groups.

[0051] The T cell population includes six different subpopulations, covering the initial state, effector, memory and exhausted T cells; we conducted a correlation analysis between these six subpopulations and the disease state of sepsis and found that the six subpopulations can form three T cell immune states (scK0, scK1, scK2), among which scK1 is characterized by high expression of GPX4 and is specifically present in sepsis. At the same time, we performed peripheral blood flow immunophenotyping and cytokine detection to further confirm the single-cell sequencing results at the protein level.

[0052] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A method for assessing the severity of a sepsis patient's condition by detecting the level of GPX4+CD8+T cells in peripheral blood, the method comprising: a. Collect peripheral blood samples from patients with sepsis; b. Treat the sample with an anticoagulant; c. Isolate PBMC cells and label them with antibodies; d. Calculate the immune cell ratio data; e. Assess the severity of the disease based on the test results; It is characterized in that the calculation of the immune cell ratio data is through flow cytometry detection of the number and ratio of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells.

2. Use of reagents for detecting the number and proportion of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells in the preparation of sepsis or sepsis prognosis diagnostic kits.

3. The use according to claim 2, characterized in that: The sample tested is blood.

4. A sepsis or sepsis prognosis diagnostic kit, characterized in that: The diagnostic kit includes reagents for detecting the number and proportion of total T lymphocytes (CD3+CD19-), total B lymphocytes (CD3-CD19+), helper / inducible T lymphocytes (CD3+CD4+), natural killer cells (CD3-CD19-CD56+), suppressor / cytotoxic T lymphocytes (CD3+CD8+), and GPX4+CD8+T cells.

5. Application of reagents for detecting GPX4+CD8+T cell subsets in the preparation of sepsis or sepsis prognosis diagnostic kits.

6. The use according to claim 5, characterized in that: The sample tested is blood.

7. A sepsis or sepsis prognosis diagnostic kit, characterized in that: The diagnostic kit comprises a reagent for detecting GPX4+CD8+T cell subpopulations.

Citation Information

Cited By

  • Biomarker combination for diagnosing chronic endometritis and application thereof

    CN120404536A